top of page

Can Trial Pricing work in Logistics & Supply Chain Technology with operational risk?

Logistics software gets purchased after a costly failure, so a trial should resolve an actual shipment, inventory or hiring workflow rather than show a feature list. Veeqo gives sellers free core shipping functionality and sells additional inventory capability; Tenstreet uses tailored enterprise pricing based on fleet and recruiting scope. Neither proves a fixed-duration Trial Pricing offer here. A warehouse that connects one channel may still suffer overselling elsewhere; a carrier cannot assess driver compliance from a fabricated application.

See how top HealthTech companies grew revenue from customers they already had, in Business Core.

✓ Skip the success story. Get the decisions behind it  ✓ Not a case study. A teardown you can copy from.

Business Core breaks down top HealthTech companies' revenue models, pricing, buyers and revenue risks, so you can see who paid for expansion and how trust was protected.

40 Foundational Decisions

34 Model Frameworks

80 Strategy Patterns

4 Pillars of any Business

Backed by evidence
On which a company is built on
Of proven growth & expansion 
Model · Market · Money · Motion

✓ Find relevant precedents in under 2 minutes   ✓ Updated every 6 months    ✓ 6 ARR stages, from pre-$1M to $100M+

Pick a decision or a strategy.
Go deep on companies that made it

Your exact comparables, one filter away.

The companies you study didn't build by instinct alone.
Neither should you.

Stop studying companies that never faced your call.
Famous case studies won’t fit your decision. These will.

​

With a Situation or Strategy you need insight on

​

Open results to see exactly how they did it - and how you can do the same.​

​

The framework walks you through every layer of how the company was built, grown & sustained big

Product & Business Model Decision
Business Model

Vanta

Sanity

Heroku

JetBrains

Todoist

Slice

Lucidchart

Trello

Bending Spoons

TheraNest

Railway

Confluent

n8n

✓ Get the Full list of companies under each   ✓ Unlock in-depth intel on each company
From “what should we do?” to a written plan in one sitting

DISTRIBUTION MODEL

Who actually pays for expansion in HealthTech: the clinician, the practice or a third party?

It depends on the model, and getting this wrong is the commonest mistake. Doximity's clinicians pay nothing while pharmaceutical and health-system buyers pay for reach, recruitment and workflow. TheraNest's therapists pay per clinician with add-ons for telehealth and claims. Benchling's scientists use the product while the enterprise pays per active user. I'd write down who signs, who uses and who benefits before choosing a meter.

How do I decide who should pay for the next HealthTech product?

• List the user, the signer and the beneficiary of the new product.

• Keep core clinician tools free only if another party reliably pays.

• Price per clinician when practices see each therapist as a unit of revenue.

• Price per active scientist when research output scales with users.

• Test whether the payer sees the value without needing the user to ask.

• Test the answer with a real customer, because the person who benefits is often not the person who asked for the tool.

Which payers and price units did Doximity, Benchling and TheraNest use in HealthTech?

The three price lists show three different payers.

• Doximity uses quote-based enterprise pricing for Marketing, Hiring and Workflow Solutions, with clinician-side tools free to maintain engagement and trust.

• Benchling uses per-user enterprise pricing with custom contracts; a third-party anchor is roughly $15,000 a year for startup plans, with large contracts reaching $1 million or more.

• TheraNest charges Essentials at $29, Advanced at $59 and Premier at $89 per therapist monthly, with telehealth at $12 for individual and $25 for group sessions.

• TheraNest payment processing and some billing services carry usage-related fees.

What did HealthTech companies show to prove their accounts would grow after adoption?

Retention and per-customer revenue. Doximity reported 119% net revenue retention in Q4 FY2025, more than 2 million registered members including over 80% of U.S. physicians, and revenue growth from $419.1 million in FY2023 to $570.4 million in FY2025. Benchling's third-party estimates put ARR near $210 million across about 1,200 customers, which are unaudited.

How do I show HealthTech investors that accounts expand when estimates are all I have?

• Shipments completed with correct inventory deduction.


• Verification time for a qualified driver application.


• Use a contained operational lane: one channel-to-shipment flow or one verified driver application, with a rollback path and signed success criteria.

What numbers did Doximity, Benchling and TheraNest cite for HealthTech expansion?

Some figures are company-reported and some are third-party estimates, so each is labelled.

• Doximity: subscription revenue of $543.8 million in FY2025 and 119% net revenue retention in Q4 FY2025; 650,000 prescribers used its workflow tools in Q2 FY2026.

• Benchling (third-party estimates): average revenue per customer rose from $125,000 in 2017-2018 to $175,000 by May 2024.

• TheraNest was founded in 2013 and became part of Therapy Brands, which KKR acquired in 2021.

• Benchling was founded in 2012 by Sajith Wickramasekara and Ashu Singhal.

HealthTech examples: which products did Doximity, Benchling and TheraNest add for existing users?

Doximity added Marketing, Hiring and Workflow Solutions, including AI documentation tools. Benchling moved from molecular-biology tools into electronic lab notebooks and wider R&D workflows. TheraNest added telehealth, claims, eligibility checks, payments, reminders and premium content around per-therapist plans.

How do I choose the next HealthTech product without breaking trust?

• Add products that make the user's day easier before products that monetise them.

• Put governance, audit trails and privacy in place before AI features.

• Price add-ons clearly, since add-on fatigue can suppress adoption.

• Avoid fragmenting the workflow into disconnected add-ons.

• Validate regulated workflows with customers before launch.

Which HealthTech companies expanded through telehealth, AI documentation or lab workflows?

Each expansion followed a daily task.

• TheraNest expanded through telehealth, claims and payments for therapists.

• Doximity expanded through workflow tools used by prescribers, alongside sales to pharmaceutical and health-system buyers.

• Benchling expanded through ELN and R&D workflows for scientists.

• Benchling's meter is the active scientist and the breadth of workflows adopted.

How to expand revenue from existing customers in your HealthTech startup

Earn trust through a daily workflow, decide who pays, then add products that support the same user. Your first decision is whether the user, the practice or a third party carries the revenue. The caution to respect is trust and compliance: don't copy enterprise monetisation before member trust is established, don't underprice compliance-heavy software, and don't deploy AI clinical tools without governance.

Business Core shows each company's revenue model, pricing, buyers and how-to-copy steps, so you can see how trust, payers and add-ons fit together.

Check the pits and revenue risks on each company page in Business Core, such as regulatory change and add-on fatigue, before you set add-on prices.

1-model (6).png

Which HealthTech revenue risks, from regulation to customer concentration, limit account growth?

Regulation, concentration and fatigue. Doximity lists pharmaceutical marketing concentration, privacy scrutiny and AI liability. Benchling lists long enterprise cycles, validation burden and scientist resistance. TheraNest lists payer and regulatory change, solo-practitioner churn and add-on fatigue.

How do I reduce HealthTech revenue risk from regulatory change and concentration?

• Budget for ongoing compliance and payer-rule maintenance.

• Spread revenue across payers so no single buyer dominates.

• Include audit and validation support in enterprise plans.

• Bundle add-ons that customers see as standard, instead of charging separately.

• Invest in support, since service failures in regulated software cause churn.

• Keep a log of every regulatory change that affected your product, and what it cost, so the budget is based on history.

Which revenue risks did Doximity, Benchling and TheraNest list in HealthTech?

The risks depend on the payer.

• Doximity lists pharmaceutical marketing concentration, regulatory and privacy scrutiny, AI accuracy risk and competition from Sermo, LinkedIn and Veeva.

• Benchling lists long enterprise cycles, implementation complexity, scientist resistance, regulatory burden and competition from ELN and LIMS vendors.

• TheraNest lists payer and regulatory change, solo-practitioner churn, price sensitivity and add-on fatigue.

• Benchling's ARR figures are third-party estimates.

How do pharma marketers, lab leaders and practice managers buy more HealthTech?

Each follows a different path. A Doximity pharmaceutical brand or health system evaluates after a need for clinician reach, recruitment or workflow modernisation, and marketing and IT leaders assess audience quality, engagement and compliance. A Benchling scientist evaluates through hands-on use and peer recommendation before procurement enters. A TheraNest therapist trials the platform and compares per-clinician cost and migration effort.

How do I handle security and compliance review when selling more HealthTech?

• Prepare a compliance pack for each product, not only the first.

• Start with hands-on use by clinicians or scientists before procurement.

• Show the migration plan and its cost.

• Give practice managers an invoice-level view of add-ons.

• Offer annual discounts for per-clinician plans.

• Ask clinicians what they would stop using if the price changed, because trust is easier to lose than to rebuild.

How did HealthTech buyers at Doximity, Benchling and TheraNest buy more?

Each buyer starts with a trigger inside their own organisation.

• Doximity: a pharmaceutical brand or health system evaluates after a need for clinician reach, recruitment or workflow modernisation.

• Benchling: the trigger is a new lab, scaling R&D, data fragmentation, regulatory preparation or a need to standardise workflows.

• TheraNest: practice growth, telehealth adoption, billing errors or administrative overload triggers evaluation.

• Benchling's procurement enters when the organisation needs security and scale.

What did HealthTech companies get wrong when trying to monetise existing users further?

They monetised before earning trust or underpriced compliance. Doximity's caution is not to copy enterprise monetisation before member trust is established and not to deploy AI clinical tools without governance. Benchling's is not to sell enterprise transformation before scientists trust the workflow. TheraNest's is not to underprice compliance-heavy software.

Which monetisation moves erode clinician trust in HealthTech?

• Advertising pressure that drains engagement.

• AI documentation without governance and audit.

• Enterprise transformation before users trust the workflow.

• Low-priced software with heavy compliance cost.

• Treating telehealth and billing as disconnected add-ons.

Which cautions did Doximity, Benchling and TheraNest write for HealthTech expansion?

Each caution protects user trust.

• Doximity: don't copy enterprise monetisation before member trust is established, and avoid AI clinical tools without governance.

• Benchling: don't sell enterprise transformation before scientists trust the workflow, and don't ignore validation and integration costs.

• TheraNest: don't underprice compliance-heavy software.

• TheraNest's second caution: don't treat telehealth or billing as disconnected add-ons.

Enter business core

How does Business Core describe the founder decisions behind revenue choices?

Each pillar opens with the founder decision the company faced and the evidence behind its choice, and there are 40 founder decisions in total.

Can I browse companies by industry in Business Core?

Reliable recruiting or verification under the carrier’s real operating requirements.

Does Business Core show which revenue risks to plan for?

Yes. The Monetization pillar lists each company's revenue risks, and the Model pillar adds the pits, traps and cautions.

Can I filter by growth engine or expansion strategy?

Yes. You can filter by growth engine and by expansion strategy, among other filters, and each matching company opens on its own page.

Business Core
Everything You Need To Build a Winning Business

Own the
playbook of companies 

that won

One-time payment · No subscription · No seat fees

Lifetime Access

Business Core

$180

180

​

​

Valid until canceled

SSL Secure Checkout. Instant access.

Companies broken down on the same 56 fields 

Filter by 40 decisions carried out by SAAS Cos.

114 model & strategy labels executed by Top Cos.

See what worked, failed and why

Leave with an ARR-stage replication blueprint

Turn proven patterns into your own strategy

​​​​

Your Business Core access is automatically added to your account on purchase.

The strategic intelligence gap closes the moment you open it.

Walk in with the decision; Walk out with companies that already made it - Here's what's INCLUDED :

MODEL

• Business Models  • Distribution Model  • Model Insights  • How to Apply it  • Opportunities & Risks

MARKET

• Market Type  • Market Entry & Foothold Strategy  • Growth Model  • Market Intelligence  • Playbook

​

MONETIZATION

• Revenue & Pricing Model  • Target Audience  • Customer Buying Behaviour  • Patterns  • Pricing Intel

MOTION

• Competitive Strategy  • Growth & Expansion Strategy • GTM Summary  • Growth Engine  • Sustaining Moats

​

bottom of page